-
The FDA has approved another HMG-CoA reductase inhibitor (statin) for the treatment of elevated cholesterol.
-
Ultralow-Dose Estrogen and Bone in Older Women; Effect of Intensity of Oral Anticoagulation in Atrial Fibrillation; Patient Knowledge and Awareness of Hypertension
-
The ECG in the Figure was obtained from a 63-year-old woman with a history of hypertension, heart failure, and atypical chest pain. Would you say there is typical LBBB (left bundle branch block)? Would you interpret this tracing as suggestive of LVH (left ventricular hypertrophy)? of acute MI (myocardial infarction)?
-
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for
the treatment of erectile dysfunction in men. Vardenafil joins
sildenafil (Viagra) as the only 2 drugs approved for this indication in
this country.
-
Schoffs and colleagues looked at the occurrence of hip fracture (excluding pathologic fractures and fractures in prosthetic hips) from 1991 to 1999 and their relationship to thiazide diuretics and chlorthalidone, which is not strictly a thiazide, but behaves like one.
-
In this sophisticated analysis of ECG-LVH regression, more than 9000 hypertensive patients were randomized to losartan or atenolol therapy, treated to target blood pressure levels, and followed for up to 5 years.
-
Weekly injections of alpha-hydroxyprogesterone caproate resulted in a substantial reduction in the rate of recurrent preterm delivery among women who were at particularly high risk for preterm delivery and reduced the likelihood of several complications in their infants.
-
The Womens Health Initiative (WHI) reports that estrogen-progestin therapy reduces fractures, but the number of gynecologic cancers observed precludes a definitive statement on the risk of endometrial and ovarian cancers.
-
As pointed out in previous OB/GYN Clinical Alerts, about 1 in 4 patients in the United States are delivered by cesarean section, a procedure still classified as a major operation.
-
A generic form of paroxetine (PaxilGlaxoSmithKline) will soon be on the market. The drug marks the second SSRI antidepressant to go generic after fluoxetine (Prozac) last year.
